AnaptysBio 3Q 2026: Revenue $30.27M, EPS $0.11 — 10-Q Summary
AnaptysBio reported 3Q 2026 revenue of $30.27M, down 60% YoY, and net income of $3.88M, down 74.4% YoY, due to the absence of a prior-year GSK milestone and higher costs. Jemperli royalties increased, while Zejula royalties declined. The company has $153M in cash and expects it to last at least 12 months.
How this was made

The 30-second read
Why it matters
The earnings miss signals short‑term weakness but the company retains sufficient cash for operations, leaving upside potential if pipeline milestones are achieved.
Market read
First‑report earnings for a US‑listed biotech; likely to move the stock on the downside.
What to watch
Cash balance of $153M provides runway, and higher Jemperli royalties could offset some revenue weakness.
Background
AnaptysBio filed its Q3 2026 Form 10‑Q, highlighting a steep revenue decline after a prior $50M GSK milestone and increased litigation costs.
Ticker impact
Q3 2026 10‑Q shows revenue down 60% YoY to $30.27M and EPS falling to $0.11, missing prior quarter.
likely pressure as the market prices in the revenue decline and missed milestone
The disclosed numbers are the first public release of the quarter and represent a material downside versus the prior period.
Market effects
Biotech sector may see broader risk‑off pressure as a peer reports a sharp revenue drop.
US biotech investors may adjust exposure to early‑stage pipelines.
Limited; impact confined to US‑listed biotech space.
Counterpoint
The drop may be temporary if upcoming GSK milestones materialize, offering a buying opportunity at lower valuations.
Key entities
- partnerGSK
Provided milestone and royalty revenue; no milestone recognized this quarter.
